Madrigal Pharmaceuticals’ Resmetirom Receives FDA Breakthrough Therapy Designation for NASH Treatment with Liver Fibrosis
Madrigal Pharmaceuticals, Inc. has received U.S. Food and Drug Administration (FDA's) Breakthrough therapy designation for resmetirom in the treatment of NASH patients with liver fibrosis. The company ...
Candel Therapeutics Receives U.S. FDA Fast Track Designation for CAN-2409 to Treat Stage III/IV NSCLC Patients
Candel Therapeutics receives FDA's fast track designation for CAN-2409, a viral immunotherapy developed to improve survival in combination with valacyclovir and pembrolizumab to treat stage III/IV non ...
SAB Biotherapeutics’ SAB-176 Granted Breakthrough Therapy Designation by FDA for High-Risk Patients with Type A and B Influenza
SAB Biotherapeutics receives the FDA's Breakthrough Therapy Designation for SAB-176, an investigational therapeutic for post-exposure prophylaxis of Type A and Type B influenza illness in high-risk pa ...